24.30
-0.12(-0.49%)
Currency In USD
| Previous Close | 24.42 |
| Open | 24.42 |
| Day High | 24.62 |
| Day Low | 23.87 |
| 52-Week High | 26.58 |
| 52-Week Low | 19.05 |
| Volume | 1.21M |
| Average Volume | 1.24M |
| Market Cap | 2.99B |
| PE | 14.21 |
| EPS | 1.71 |
| Moving Average 50 Days | 23.69 |
| Moving Average 200 Days | 22.3 |
| Change | -0.12 |
If you invested $1000 in Catalyst Pharmaceuticals, Inc. (CPRX) 10 years ago, it would be worth $20,593.22 as of February 21, 2026 at a share price of $24.3. Whereas If you bought $1000 worth of Catalyst Pharmaceuticals, Inc. (CPRX) shares 5 years ago, it would be worth $5,677.57 as of February 21, 2026 at a share price of $24.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
GlobeNewswire Inc.
Feb 11, 2026 1:03 PM GMT
The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ETCORAL GABLES, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage bioph
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
GlobeNewswire Inc.
Jan 08, 2026 1:03 PM GMT
CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
GlobeNewswire Inc.
Jan 05, 2026 1:03 PM GMT
Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning IntensiveCORAL GABLES, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The University of Notre Dame and Catalyst Pharmaceuticals, Inc. (“Catalyst”